Galcanezumab
ATC Code
N02CD02
Galcanezumab
Definition
A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting calcitonin-gene related peptide (CGRP) ligand, that can be used in the preventive treatment of migraine. Upon subcutaneous administration, galcanezumab specifically targets and binds to CGRP ligand, and blocks the binding of the CGRP ligand to its receptor. This blocks the CGRP pathway and prevents migraine.
Also known as Emgality, GALCANEZUMAB, Galcanezumab-gnlm — per NCIT
Also identified as
- ATC N02CD02 per RXNORM
- NCIT NCIT:C166816 per NCIT
- SCTID 782371005 per RXNORM
- SCTID 782419003 per RXNORM
- UNII 55KHL3P693 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Migraine | may prevent | MEDRT · Public domain (U.S. Government work) |
| Cluster headache syndrome | may treat | MEDRT · Public domain (U.S. Government work) |